Progress in the development of small molecule inhibitors of insulin-like growth factor-1 receptor kinase

被引：11

作者：

Sarma, P. K. S.

Tandon, Ruchi

Gupta, Praful

Dastidar, Sunanda G.

Ray, Abhijit

Das, Biswajit

Cliffe, Ian A.

机构：

[1] Ranbaxy Res Labs, Dept Med Chem, Gurgaon 122001, Haryana, India

[2] Ranbaxy Res Labs, Dept Pharmacol, Gurgaon 122001, Haryana, India

[3] Ranbaxy Res Labs, Dept Med Chem, Gurgaon 122001, Haryana, India

来源：

EXPERT OPINION ON THERAPEUTIC PATENTS | 2007年 / 17卷 / 01期

关键词：

dual inhibitor; IGF-1; receptor; insulin receptor; small molecule inhibitor;

D O I：

10.1517/13543776.17.1.25

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Insulin-like growth factor-1 receptor (IGF-1R) is a receptor tyrosine kinase that plays a key role in tumor cell proliferation and in the inhibition of apoptosis, and therefore is a potential target for the treatment of cancer. The blockade of IGF-1R kinase activity by small molecule binding to the catalytic domain of the receptor offers promise for the future and this review summarizes the patent literature from 2000 to early 2006.

引用

页码：25 / 35

页数：11

共 78 条

[1]

*AM ASS CANC RES, 2005, 96 ANN M AM ASS CANC, P96

[2]

*AM SOC CLIN ONC, 2006, 42 AM SOC CLIN ONC A

[3]

AMGEN INC, 2003, Patent No. 03018021

[4]

AMGEN INC, 2003, Patent No. 03018022

[5]

[Anonymous], [No title captured], Patent No. 2005097800

[6] INTERFERENCE OF THE IGF SYSTEM AS A STRATEGY TO INHIBIT BREAST-CANCER GROWTH [J].

ARTEAGA, CL .

BREAST CANCER RESEARCH AND TREATMENT, 1992, 22 (01) :101-106

[7]

ASTRAZENECA AB, 2003, Patent No. 03048133

[8]

AVENTIS PHARM SA, 2003, Patent No. 003078402

[9]

AXELAR AB, 2004, Patent No. 2004054996

[10]

AXELAR AB, 2004, Patent No. 2004055022

← 1 2 3 4 5 6 7 8 →